ArticleThe Science of the total environment2026
Associations between prenatal per- and polyfluoroalkyl substances (PFAS) and repeated measures of bioactive lipids during pregnancy in the LIFECODES cohort.
Article in The Science of the total environment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionPer- and polyfluoroalkyl substances (PFAS) are a group of synthetic chemicals used in consumer products and industrial applications. Higher prenatal PFAS levels have been linked to adverse pregnancy outcomes, yet underlying biological mechanisms are not well understood, although disruptions in inflammatory processes are suspected.
objectivesExamine associations between prenatal PFAS exposure and maternal bioactive lipid concentrations during pregnancy.
methodsWe included 436 participants from the racially and socioeconomically diverse LIFECODES cohort in Boston, Massachusetts. Maternal plasma samples collected in early pregnancy [median gestation = 10 weeks] were analyzed for nine PFAS, while a panel of 55 bioactive lipids, including polyunsaturated fatty acid precursors and their oxylipin derivatives, were assessed in samples collected at up to two gestational time points (median gestation = 9.6 and 26 weeks). We examined associations between individual PFAS and repeated measures of bioactive lipids using generalized estimating equation models, adjusting for maternal demographic, socioeconomic, and study-related factors. We additionally conducted study visit- and fetal sex-stratified analyses.
resultsHigher concentrations of certain PFAS were associated with significant changes in bioactive lipid levels, with direction and magnitude varying by specific PFAS, bioactive lipid, and gestational timing. Several PFAS were inversely associated with prostaglandins (PGs), hydroxyeicosatetraenoic acids (HETEs), and oxoeicosatetraenoic acids (oxoETEs) across multiple enzymatic pathways. In contrast, we observed positive associations of several PFAS with leukotriene B4 (LTB4), with an interquartile range (IQR) increase in perfluorooctanoic acid (PFOA) leading to a 14.35% (95% CI: 5.03, 24.5) increase in LTB4 levels. Stratified analysis showed generally stronger associations at the earlier gestational time point than at the later time point, while trends by fetal sex were inconsistent.
conclusionsPrenatal PFAS exposure was associated with alterations in maternal bioactive lipid levels, particularly derivatives of arachidonic acid. These shifts suggest that disruption of arachidonic acid metabolism may be an important pathway through which PFAS may exert their biological effects, warranting further mechanistic investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.